ClinicalTrials.gg
CompletedNCT00333086Updated Apr 19, 2012

A Study of Letrozole in the Treatment of Endometrial Cancer

A Phase 2 interventional study of Letrozole in Recurrent and Metastatic Endometrial Cancer, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-19.

Primary conditionEndometrial NeoplasmsRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Endometrial Neoplasms
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Endometrial Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing letrozole in Endometrial Neoplasms — 5 open to participants now, 9 under way, 3 of them phase 3. Letrozole · Endometrial Neoplasms.

Enrollment
12th of 17
36 · median 53
Started
2000
with 1 other
Phase 2
12 of 17
2 open now
Registered
3rd of 17
by date
Lead sponsor
2 of 17
Novartis Pharmaceuticals

Among the 17 studies testing letrozole in Endometrial Neoplasms, this one is the 12th largest by enrollment, is one of 2 that started in 2000, is one of 12 in phase 2, and was the 3rd registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

5 of the 17 studies testing letrozole in Endometrial Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing letrozole in Endometrial Neoplasms, or all of them as a file.
02

Study summary

Currently available treatments for endometrial cancer are associated with limited efficacy and significant toxicity. This study will assess the safety and efficacy of letrozole, an aromatase inhibitor, on endometrial cancer.

03

Conditions studied

  • Recurrent and Metastatic Endometrial Cancer

Browse trials for

Keywords

  • Endometrial Cancer
  • Aromatase inhibitor
  • Letrozole
04

In context

Endometrial Neoplasms Reclassified

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

This study's enrollment of 36 is below the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.

Browse Endometrial Neoplasms studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.

Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Endometrial Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women with recurrent or adeno- or adenosquamous carcinoma of the endometrium
  • No therapy
  • Up to one prior hormonal (progestin) therapy for advanced/metastatic disease allowed
  • No chemotherapy for recurrence (adjuvant permitted)
  • Unidimensionally
  • Good Health status 0-2 (Eastern Cooperatitve Oncology Group)
  • No prior tamoxifen or aromatase inhibitor therapy
  • No other concurrent anti-cancer treatment
  • No metastases in the central nervous system

Exclusion criteria

Exclusion criteria:

Additional protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Interventions

07

What researchers measure

Primary outcomes

  1. Response rates (complete response, partial response, no change, progressive disease) measured by tumor marker assessments and radiologic imaging at week 12 then every 12 weeks x 1 year followed by every 16 weeks

Secondary outcomes

  1. Duration of clinical response, time to progression of the disease, correlation of tumor response with pretreatment ER/PR status, histological grade and aromatase levels

08

Study locations

1 site
  • Novartis Investigative Site
    Heidelberg, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2000 and a primary completion of Jun 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2006
First posted
Jun 2, 2006
Start
Jan 2000
Primary completionActual
Jun 2006
Last update
Apr 19, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00333086
Collaborators
Canadian Cancer Trials Group
Responsible party
Sponsor
First posted
Jun 2, 2006
Start date
Jan 2000
Primary completion
Jun 2006
Last update
Apr 19, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion